Improved Glucose Control and Reduced Body Weight in Rodents with Dual Mechanism of Action Peptide Hybrids

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Trevaskis, James L ^a   Mack, Christine M ^a   Sun, Chengzao ^a   Soares, Christopher J ^a   D'Souza, Lawrence J ^a   Levy, Odile E ^a   Lewis, Diane Y ^a   Jodka, Carolyn M ^a   Tatarkiewicz, Krystyna ^a   Gedulin, Bronislava ^a   Gupta, Swati ^a   Wittmer, Carrie ^a   Hanley, Michael ^a   Forood, Bruce ^a   Parkes, David G ^a   Ghosh, Soumitra S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 164204; AC 164209; AC 3082; AMYLIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CALCITONIN RECEPTOR; DAVALINTIDE; EXENATIDE[1-28]; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; PEPTIDE HYBRID; UNCLASSIFIED DRUG; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HBA(1C) PROTEIN, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FOOD INTAKE; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEAN BODY WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; WEIGHT REDUCTION; AGONISTS; ANIMAL; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; MALE; MICE; MICE, OBESE; OBESITY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON;

EID: 84886049149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078154     Document Type: Article

References (42)

1. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053. doi:10.2337/diacare.27.5.1047. PubMed: 15111519.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644. PubMed: 19805654.
3. Resnick HE, Foster GL, Bardsley J, Ratner RE, (2006) Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29: 531-537. doi:10.2337/diacare.29.03.06.dc05-1254. PubMed: 16505501.
4. Turner R, Holman R, Butterfield J, (1999) UKPDS: what was the question? UK Prospective Diabetes Study. Lancet 354: 600. doi:10.1016/S0140-6736(05)77957-5.
5. Howes LG, (2000) Cardiovascular effects of sulphonylureas: role of K(ATP) channels. Diabetes Obes Metab 2: 67-73. doi:10.1046/j.1463-1326.2000.00047.x. PubMed: 11220526.
6. Drucker DJ, (2006) The biology of incretin hormones. Cell Metab 3: 153-165. doi:10.1016/j.cmet.2006.01.004. PubMed: 16517403.
7. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635. doi:10.2337/diacare.27.11.2628. PubMed: 15504997.
8. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091. doi:10.2337/diacare.28.5.1083. PubMed: 15855571.
9. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, et al. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481. doi:10.1016/S0140-6736(08)61246-5. PubMed: 18819705.
10. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, et al. (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32: 762-768. doi:10.2337/dc08-1797. PubMed: 19196887.
11. Laugero KD, Stonehouse AH, Guss S, Landry J, Vu C, et al. (2009) Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome. Metab Syndr Relat Disord.
12. Sonne DP, Engstrøm T, Treiman M, (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-249. doi:10.1016/j.regpep.2007.10.001. PubMed: 17976835.
13. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, et al. (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510. doi:10.1016/j.jacc.2008.10.033. PubMed: 19195607.
14. Amori RE, Lau J, Pittas AG, (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206. doi:10.1001/jama.298.2.194. PubMed: 17622601.
15. Young A, editor (2005) Amylin: physiology and pharmacology. Amsterdam; Boston: Elsevier/Academic Press, Inc.
16. Weyer C, Maggs DG, Young AA, Kolterman OG, (2001) Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control [Published correction appears in Curr Pharm Des (2001); 7: 1353]. Curr Pharm Des 7-1373. PubMed: 11472273.
17. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, et al. (2008) Sustained weight loss following 12 months pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31: 1816-1823. doi:10.2337/dc08-0029. PubMed: 18753666.
18. Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, et al. (2010) Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond) 34: 385-395. doi:10.1038/ijo.2009.238. PubMed: 19935749.
19. Schnölzer M, Alewood P, Jones A, Alewood D, Kent SB, (1992) In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 40: 180-193. PubMed: 1478777.
20. Hackeng TM, Griffin JH, Dawson PE, (1999) Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U S A 96: 10068-10073. doi:10.1073/pnas.96.18.10068. PubMed: 10468563.
21. Parkes DG, Pittner R, Jodka C, Smith P, Young A, (2001) Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50: 583-589. doi:10.1053/meta.2001.22519. PubMed: 11319721.
22. Dawson PE, Kent SB, (2000) Synthesis of native proteins by chemical ligation. Annu Rev Biochem 69: 923-960. doi:10.1146/annurev.biochem.69.1.923. PubMed: 10966479.
23. Dawson PE, Muir TW, Clark-Lewis I, Kent SB, (1994) Synthesis of proteins by native chemical ligation. Science 266: 776-779. doi:10.1126/science.7973629. PubMed: 7973629.
24. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, et al. (2013) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 37: 322 doi:10.1038/ijo.2012.192. PubMed: 21844879.
25. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286. doi:10.1185/030079908X253870. PubMed: 18053320.
26. Heal DJ, Gosden J, Smith SL, (2013) A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes (Lond) 37: 107-117. doi:10.1038/ijo.2012.26.
27. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, et al. (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 17: 1736-1743. doi:10.1038/oby.2009.184. PubMed: 19521351.
28. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, et al. (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105: 7257-7262. doi:10.1073/pnas.0706473105. PubMed: 18458326.
29. Claus TH, Pan CQ, Buxton JM, Yang L, Reynolds JC, et al. (2007) Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J Endocrinol 192: 371-380. doi:10.1677/JOE-06-0018. PubMed: 17283237.
30. Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, et al. (2012) Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98: 443-450. doi:10.1002/bip.22072. PubMed: 23203689.
31. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757. doi:10.1038/nchembio.209. PubMed: 19597507.
32. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, et al. (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258-2266. doi:10.2337/db09-0278. PubMed: 19602537.
33. Drucker DJ, (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1: 22-31. doi:10.1038/ncpneuro0033. PubMed: 16929363.
34. Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, et al. (2008) Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Int J Obes (Lond).
35. Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, et al. (2007) Combination Therapy with Amylin and Peptide YY 3-36 in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity. Endocrinology 148: 6054-6061. doi:10.1210/en.2007-0898. PubMed: 17761760.
36. Roth JD, D'Souza L, Griffin PS, Athanacio J, Trevaskis JL, et al. (2012) Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents. Diabetes Obes Metab 14: 608-615. doi:10.1111/j.1463-1326.2012.01570.x. PubMed: 22276636.
37. Bhavsar S, Watkins J, Young A, (1998) Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 64: 557-561. doi:10.1016/S0031-9384(98)00110-3. PubMed: 9761232.
38. Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, et al. (2010) Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin? Physiol Behav 100: 187-195. doi:10.1016/j.physbeh.2010.02.023. PubMed: 20206194.
39. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, et al. (2008) Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149: 5679-5687. doi:10.1210/en.2008-0770. PubMed: 18669592.
40. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100. doi:10.2337/diacare.28.5.1092. PubMed: 15855572.
41. Bello NT, Kemm MH, Ofeldt EM, Moran TH, (2010) Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol 299: R945-R952. doi:10.1152/ajpregu.00275.2010. PubMed: 20554932.
42. Roth JD, Erickson MR, Chen S, Parkes DG, (2012) GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol 166: 121-136. doi:10.1111/j.1476-5381.2011.01537.x. PubMed: 21671898.